Abstract:BackgroundIn this study, we evaluated the ability of radiomic textural analysis of intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC).MethodsA total of 117 patients who had received NAC were retrospectively analyzed. Within the intratumoral and peritumoral regions of T1-weighted contrast-enhanced MRI scans, a total of 99 radiomic textural features were computed at multiple phases. Feature selection was used to identify a set of top pCR-associated features from within a training set (n = 78), which were then used to train multiple machine learning classifiers to predict the likelihood of pCR for a given patient. Classifiers were then independently tested on 39 patients. Experiments were repeated separately among hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+, HER2−) and triple-negative or HER2+ (TN/HER2+) tumors via threefold cross-validation to determine whether receptor status-specific analysis could improve classification performance.ResultsAmong all patients, a combined intratumoral and peritumoral radiomic feature set yielded a maximum AUC of 0.78 ± 0.030 within the training set and 0.74 within the independent testing set using a diagonal linear discriminant analysis (DLDA) classifier. Receptor status-specific feature discovery and classification enabled improved prediction of pCR, yielding maximum AUCs of 0.83 ± 0.025 within the HR+, HER2− group using DLDA and 0.93 ± 0.018 within the TN/HER2+ group using a naive Bayes classifier. In HR+, HER2− breast cancers, non-pCR was characterized by elevated peritumoral heterogeneity during initial contrast enhancement. However, TN/HER2+ tumors were best characterized by a speckled enhancement pattern within the peritumoral region of nonresponders. Radiomic features were found to strongly predict pCR independent of choice of classifier, suggesting their robustness as response predictors.ConclusionsThrough a combined intratumoral and peritumoral radiomics approach, we could successfully predict pCR to NAC from pretreatment breast DCE-MRI, both with and without a priori knowledge of receptor status. Further, our findings suggest that the radiomic features most predictive of response vary across different receptor subtypes.

Intra-Tumor Partitioning and Texture Analysis of Dce-Mri Identifies Relevant Tumor Subregions to Predict Early Pathological Response of Breast Cancer to Neoadjuvant Chemotherapy

Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.

Early Prediction of Breast Cancer Therapy Response to Neoadjuvant Chemotherapy through Texture Analysis of DCE-MRI

Texture Features of Pre-Operative Contrast Enhanced MRI Early Phase Images in Predicting Complete Response for Breast Cancer after Neoadjuvant Chemotherapy

Dynamic Contrast-Enhanced Magnetic Resonance Imaging For Prediction Of Response To Neoadjuvant Chemotherapy In Breast Cancer

Radiomic Analysis of DCE-MRI for Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.

Texture Analysis Based on Contrast-Enhanced MRI Can Predict Treatment Response to Neoadjuvant Chemotherapy of Breast Cancer

Association Between Dynamic Features of Breast Dce-Mr Imaging and Clinical Response of Neoadjuvant Chemotherapy: A Preliminary Analysis

Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer

Radiomics of Tumor Heterogeneity in Longitudinal Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer

Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer

Radiomics Analysis of Multi-Phase DCE-MRI in Predicting Tumor Response to Neoadjuvant Therapy in Breast Cancer

DCE-MRI Texture Analysis with Tumor Subregion Partitioning for Predicting Ki-67 Status of Estrogen Receptor-Positive Breast Cancers.

Automated Quantification of Background Parenchymal Enhancement in Longitudinal Dynamic Contrast-Enhanced MRI for Predicting Neo-adjuvant Chemotherapy Response in Breast Cancer

Early prediction of pathological response to neoadjuvant chemotherapy of breast tumors: a comparative study using amide proton transfer-weighted, diffusion weighted and dynamic contrast enhanced MRI

Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI

MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

Texture Analysis of Dynamic Contrast-Enhanced MRI in Evaluating Pathologic Complete Response (pcr) of Mass-Like Breast Cancer after Neoadjuvant Therapy.

Textural radiomic features and time-intensity curve data analysis by dynamic contrast-enhanced MRI for early prediction of breast cancer therapy response: preliminary data

Predicting Pathological Response after Neoadjuvant Chemotherapy of Breast Cancer Using Pharmacokinetic Histogram Features on Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Contrast-enhanced Ultrasonography for Early Prediction of Response of Neoadjuvant Chemotherapy in Breast Cancer